SAGA Diagnostics

We are excited to be sponsoring the upcoming World CB & CDx conference taking place in Boston in early September. We look forward to seeing you there! 🚀 #oncology #mrd #residualdisease #clinical trials #biomarkers #liquidbiopsy

#ICYMI At #ASCO24 we presented two posters with our valued collaborators showcasing our latest MRD data in early breast cancer and epithelial ovarian cancer. 🧬 Monitoring ctDNA dynamics in early breast cancer using a novel ultra-sensitive tumor-informed structural variant approach combining whole-genome sequencing and multiplex dPCR 🧬 Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer You can view the posters now on our website https://lnkd.in/eCMmuK5P #MRD #ClinicalDiagnostics #oncology #breastcancer #ovariancancer

On #ResearchAppreciationDay and every day, we share our thanks and gratitude 🙏 for our exceptional R&D team 🧬 who work tirelessly to bring new and innovative diagnostic solutions to patients living with cancer. 📣 We have exciting new opportunities to join our R&D team. Both roles are based in RTP, North Carolina working with our SVP Research and Development Samuel Woodhouse - Associate Director/Director of Technology Transfer - Senior Application Scientist If you are fueled by a passion to push the boundaries in oncology ,then you could be the new team members we are looking for. For more information and to apply https://lnkd.in/e8HyNYaH #MRD #jobs #OpenRoles #Oncology #ClinicalDiagnostics

More opportunities to join the SAGA team are now live! 🎉 Check out the roles currently open on our Clinical team. Open to applicants in Lund, Sweden and Morrisville, North Carolina.

#TeamSaga are looking forward to another great day at #ASCO24! Please visit us at booth #11048 during the exhibition hours to meet our team and find out more about our #MRD capabilities.

Join us this weekend at the annual #ASCO24 conference. We will be presenting along with our valued collaborators two posters on June 2 and 3 showcasing our latest MRD data in early breast cancer and epithelial ovarian cancer. See you in the poster sessions! #MRD #clinicaldiagnostics #oncology #breastcancer #ovariancancer

We’ve hit the ground running ready for #ASCO24 in Chicago! Please contact us to set up a meeting and make sure to visit booth #11048 during the exhibition times to discuss our game-changing approach to MRD testing and our latest data. Peter Collins Chris Abbosh Patrick Eimerman Karen Howarth #MRD #clinicaldiagnostics #oncology #breastcancer #ovariancancer

At #ASCO24 we will be presenting two posters in partnership with our collaborators including data from postoperative residual disease in Epithelial Ovarian Cancer and a novel ultra-sensitive tumor-informed structural variant approach combining whole-genome sequencing and multiplex dPCR for monitoring MRD and ctDNA dynamics in early breast cancer. #MRD #clinicaldiagnostics #oncology #breastcancer #ovariancancer

#TeamSAGA is looking forward to #ASCO24 Our executive, clinical and business teams will be onsite and available to meet with potential partners in Chicago, May 31 to June 4 to discuss our game-changing approach to MRD testing. At SAGA we never lose sight of our guiding purpose to bring comfort, confidence and control to cancer therapy decision-making. Contact us to set up a meeting and make sure to visit booth #11048. See you soon in Chicago! #MRD #clinicaldiagnostics #oncology #breastcancer #ovariancancer Karen Howarth Peter Collins Patrick Eimerman Chris Abbosh

SAVE THE DATE! #ASCO24 is just around the corner. Join us at this year’s conference to hear the latest updates on our transformative MRD testing platform. Meet us at booth #11048 or book a 1-2-1 meeting with our BD and partnering team. #MRD #clinicaldiagnostics #oncology #breastcancer #ovariancancer